Compounding Nasal Irrigations
Compounding Nasal Irrigations
Sarah Taylor, PharmD
What is the role of nasal irrigations and when are they used?
Chronic rhinosinusitis is a condition that occurs when the lining
of the sinuses becomes infected, irritated, or inflamed. The prevalence
of rhinosinusitis globally is estimated to be as high as 12%
and incidence in the US is thought to be 1-5%.1,2 To be considered
chronic, rhinosinusitis must have occurred for at least 12 consecutive weeks.2
Conventional treatments may include irrigations with saline,
intranasal corticosteroid nasal sprays, short courses of oral steroids, or even
oral antibiotics.2 When conventional treatments are not successful,
alternatives such as corticosteroids for nasal irrigation are sometimes
considered.2 One
study of 12 patients suffering from chronic rhinosinusitis with nasal polyps
and asthma treated patients with 0.5mg budesonide in 250ml normal saline. Half
the volume was applied in each nostril twice daily for six months. The
treatment was noted to be effective and to reduce the need for oral steroid
intake.3 In addition to steroids, antibiotics are also sometimes
used topically for nasal irrigation. One review of 58 patients suffering from
chronic rhinosinusitis tested the utility of topical antibiotics based on
susceptibility of the microbe to various antimicrobials. The antibiotics selected for these patients
included tobramycin 100mg/100ml, vancomycin 200mg/100ml, levofloxacin
100mg/100ml, mupirocin 15mg/100ml, gentamicin 80mg/100ml, ceftriaxone
200mg/100ml, and ceftazidime 600mg/100ml. Patients irrigated each nostril with
50ml twice daily for 30 days. The study found that topical antibiotics resulted
in improved symptom severity and significantly improved endoscopic appearance.
Additionally, 72% of patients treated with topical antibiotics had negative
posttreatment culture results.4 Anti-fungal nasal irrigations, such
as those containing amphotericin B at 100mcg/ml or 200mcg/ml, have also been
evaluated for chronic rhinosinusitis, however, current data has not noted
benefit over normal saline nasal irrigation.5 Though data is
currently limited for many of these irrigation treatments, existing information
supports potential utility for some of these active pharmaceutical ingredients
(APIs) delivered topically nasally in those who are unable to find resolution
with commercially available options.
Are nasal sprays and irrigations required to be sterile?6
Under current and proposed USP <795>, nasal sprays and
irrigations are not required to be sterile. Proposed USP <795> guidelines
lay out under section 1.1 (Scope) examples of what may be considered as a
compounded nonsterile preparation (CNSP):
·
Solid oral preparations
·
Liquid oral preparations
·
Rectal preparations
·
Vaginal preparations
·
Topical preparations (i.e. creams, gels, and
ointments)
·
Nasal and sinus preparations intended for
local application (i.e. nasal sprays and nasal irrigation)
·
Otic preparations (excluding use in perforated
eardrums)
How are nasal irrigations dispensed?
Nasal irrigations may be dispensed as premade liquids in vehicles
safe for application to the sinuses, such as sterile water for irrigation, USP,
or sodium chloride 0.9% for irrigation, USP.1,3,4 For ingredients
that are subject to rapid degradation in aqueous environments or for volumes
that are difficult or impractical to dispense or ship, a dry form such as a
capsule with an appropriate dispersible and soluble capsule filler could be
considered. Capsules for nasal irrigation are dispensed to the patient who then
opens them into appropriate solution for nasal irrigation and mixes prior to
application. Dry powder dosage forms such as capsules allow for an extended
beyond use date (BUD) per current and proposed USP <795> guidelines and
are more easily transported by the pharmacy and patient compared to large
volumes of premade irrigation solution.
What is DispersaPro and how does it work?
DispersaPro is a
micronized powder excipient designed to assist in the delivery of various APIs
for non-sterile irrigation applications. Fagron DispersaPro powder contains
poloxamers, which have been found in some studies to help disperse and
solubilize poorly soluble APIs.7 It also contains xylitol, an
ingredient that has been studied for its potential utility against biofilms.8
DispersaPro offers an anhydrous alternative for delivery of APIs with unknown
or poor stability in aqueous vehicles, allowing patients to open capsules or
packets containing DispersaPro immediately prior to use and disperse the powder
in an aqueous vehicle for non-sterile irrigation applications, such as nasal
irrigation.
For
further inquiries on nasal irrigations or formulations, reach out to the Fagron
Academy team using our FACTS Questions
form
Sources:
1.
Xu Y, Quan H,
Faris P, et al. Prevalence and Incidence of Diagnosed Chronic Rhinosinusitis in
Alberta, Canada. JAMA Otolaryngol Head Neck Surg. 2016;142(11):1063–1069.
doi:10.1001/jamaoto.2016.2227
2.
Sedaghat A,
Chronic Rhinosinusitis. Am Fam
Physician. 2017 Oct 15;96(8):500-506.
3.
Kang TW, Chung JH, Cho SH, Lee SH, Kim KR,
Jeong JH. The Effectiveness of Budesonide Nasal Irrigation After Endoscopic
Sinus Surgery in Chronic Rhinosinusitis With Asthma. Clin Exp Otorhinolaryngol.
2017;10(1):91-96. doi:10.21053/ceo.2016.00220
4.
Lee VS, Davis GE. Culture-directed topical
antibiotic treatment for chronic rhinosinusitis. Am J Rhinol Allergy.
2016;30(6):414-417. doi:10.2500/ajra.2016.30.4380
5.
Ebbens F, Scadding G, Badia L et al.
Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis.
Rhinitis, Sinusitis, and Ocular Diseases. 2006; 116(5): P1149-1156.
DOI:https://doi.org/10.1016/j.jaci.2006.07.058
6.
United States Pharmacopeia and National
Formulary. USP <795> Pharmaceutical Compounding – Nonsterile
Preparations. Current DocID:
GUID-98DCB48D-DC23-4A63-AD2E-01CA8979FB7E_5_en-US
7.
Bodratti AM, Alexandridis P. Formulation of
Poloxamers for Drug Delivery. J Funct Biomater. 2018;9(1):11.
Published 2018 Jan 18. doi:10.3390/jfb9010011
8.
Jain R, Lee T, Hardcastle T, Biswas K,
Radcliff F, Douglas R. The in vitro effect of xylitol on chronic rhinosinusitis
biofilms. Rhinology. 2016 Dec 1;54(4):323-328. doi: 10.4193/Rhino15.380. PMID:
27394715.
Comments
Post a Comment